The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Emergent BioSolutions Secures $18M CAD NARCAN Supply Deal in British Columbia

Key Facts

1Emergent BioSolutions announced a partnership with the B.C. Provincial Health Services Authority to supply NARCAN Nasal Spray.

Emergent BioSolutions (NYSE: EBS) has announced a significant partnership with the British Columbia Provincial Health Services Authority to supply NARCAN Nasal Spray. The provincial government is investing an additional $18 million CAD to expand its Take-Home Naloxone Program, incorporating the nasal version of the life-saving medication. This expansion follows a successful 2024 pilot program that saw the distribution of 60,000 nasal naloxone kits across various community sites. The initiative aims to enhance the response to the opioid crisis by making NARCAN more accessible through pharmacies, fire departments, and community centers. For Emergent BioSolutions, this agreement secures a stable, government-backed revenue stream and reinforces its leadership in the North American naloxone market. Investors view this development as a positive step for the company's pharmaceutical portfolio and public health footprint.